DePuy ASR recall takes $271M from J&J’s Q1 bottom line

April 18, 2012 By MassDevice staff Leave a Comment

Shares of Johnson & Johnson (NYSE:JNJ) closed up a hair yesterday after the company said it added 12.5% to its bottom line, ending the day at $64.22 per share after the J&J raised its earnings guidance for the year by a pair of pennies.

The New Brunswick, N.J.-based health care conglomerate said costs associated with the recall of its DePuy ASR metal-on-metal hip implant and with litigating the 100s of personal injury lawsuits filed over the device slashed $271 million from its quarterly profits.

J&J posted profits of $3.91 billion, or $1.41 per share, on sales of $16.14 billion for the quarter, for essentially flat sales compared with profits of $3.48 billion, or $1.25 EPS, on sales of $16.17 billion during Q1 2011.

Excluding 1-time items such as the DePuy recall expenses, adjusted EPS were $1.37, 2¢ above analysts’ consensus of $1.35.

"We continue to bring meaningful innovations to our patients and customers through the strong performance of our recently launched products," said outgoing chairman & CEO William Weldon, who’s slated to cede the corner office to Alex Gorsky next week, in prepared remarks. "The dedication of the people of Johnson & Johnson gives me great confidence in the prospects of our business to deliver sustainable growth, well into the future."

Johnson & Johnson raised its top-line adjusted EPS guidance for 2012 from $5.05-$5.15 to $5.07-$5.17. Analysts on The Street are predicting adjusted EPS of $5.10 for the year.

Sales for J&J’s medical device & diagnostics segment were flat at $6.41 billion, down 0.3% compared with $6.43 billion during the same period last year. That’s largely due to a 24.1% slide for its cardiovascular unit, driven in turn by its move to exit the coronary stent business last year.

Orthopedic product sales were off by 0.7% for the quarter, at $1.49 billion. General surgery product sales rose a tick to $1.63 billion, while specialty surgery sales jumped 8.8% to $628 million.

JNJ shares opened today at $63.90, down about 0.01%.

Certain GE Healthcare patient-monitoring devices vulnerable to cyberattack
The federal government and GE Healthcare (NYSE:GE) announced today that the certain of the company’s patient monitoring devices are vulnerable to cyberattack. If attacked, some versions of the Carescape and ApexPro telemetry servers, the Carescape Central Station version 1 and Central Information Center systems could stop monitoring patients, silence alarms or produce unnecessary alarms during… […]
Cardinal Health recalls 9 million surgical gowns, sends hospitals scrambling
Cardinal Health (NYSE:CAH) announced that it is voluntarily recalling 9.1 million surgical gowns produced by an unnamed contract manufacturer after discovering quality issues with the product. The Dublin, Ohio-based company said that some gowns were produced in unapproved locations that did not maintain proper environmental conditions as required by law. Some of the gowns were also… […]
KNF launches compact swing piston pump
KNF Neuberger is touting its NPK 06 swing piston micro gas pumps, designed to deliver high-flow and high-pressure performance in a compact size. The new pumps work well for medical diagnostics, therapy, monitoring, and general compression applications, according to the Trenton, N.J.-based company. NPK 06 measures 1.85” (47mm) wide and can produce free flow up… […]
Heraeus Medical Components and Myant partner on electrical sensing for textiles
Heraeus Medical Components (St. Paul, Minn.) and Toronto-based Myant have entered a partnership enabling Myant to use Heraeus’ Tectitoat for electrical sensing applications in textiles, the companies announced today. Tecticoat is a conductive polymer-based coating that can be applied to textiles to control electrical conductivity, electromagnetic shielding and electrostatic dissipation, making it suitable for integration… […]
Cook Medical’s peripheral artery set debuts in U.S.
Cook Medical recently announced the U.S. launch of its TriForce peripheral crossing set to support vascular obstruction procedures. The TriForce set is designed to be percutaneously introduced into blood vessels to support a wire guide while performing a peripheral intervention, according to the Bloomington, Ind.-based company. This device is also intended for injection of radiopaque… […]
Bayer and Exscientia partner to bring AI to drug discovery
Bayer (ETR:BAYN) announced that it is entering into a collaboration agreement with artificial intelligence drug discovery company Exscientia to identify and optimize novel lead structures for potential drug candidates in treating cardiovascular and oncological diseases. The agreement, announced earlier this month, is slated to see the companies work together on early research projects combining Exscientia’s proprietary… […]
GHO Capital acquires Ardena
European specialist investor Global Healthcare Opportunities, also called GHO Capital Partners, recently announced that it has acquired Ardena — a specialist contract development and manufacturing organization focused on early phase drug development. Financial terms of the deal, announced Jan. 9, were not disclosed. Get the full story on sister site Drug Discovery and Development. The […]
Albright Silicone launches 3D printed tooling for silicone molding
Albright Silicone (Leominster, Mass.) recently announced that it has added 3D printed tooling for LSR molding, touting the relative low coast and rapid turnaround the process offers for prototyping. “This capability of 3D printing and molding LSR is a helpful solution to customers’ problems when trying to develop and prove a concept before investing in… […]
BREAKING: Medtronic wins FDA approval for Micra AV
Medtronic (NYSE:MDT) has won FDA approval for its Micra AV — greatly expanding the number of people who could potentially benefit from leadless pacemaker technology. The medical device giant plans to start offering the Micra AV in a limited number of implanting centers in the coming weeks, with a full launch expected in the spring. FDA… […]
FDA reclassifies some medical image analyzers
The FDA today imposed stricter regulations on certain radiological medical image analyzers, reclassifying them from Class III to Class II. Affected products include computer-assisted detection (CADe) devices for breast cancer mammography, breast-lesion ultrasound, and lung-nodule and dental-caries radiography, the agency said. It defines these devices as those intended to identify, mark, highlight, or in any… […]
Medline Industries temporarily halts EtO sterilization at Illinois plant
This article has been updated with a comment from Medela. Medline Industries has temporarily closed its Waukegan, Ill., medical device sterilization operation to install nearly $10 million in emissions upgrades. The privately owned company uses the carcinogenic gas ethylene oxide (EtO) to sterilize its own and other companies’ devices at the plant. Medline did not… […]